FDA Relies On Cognition Research To Spot Misleading Ads – Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA is harnessing established science on human cognition to assess whether a device or drug maker's advertisement is misleading, according to a May 27 draft 1guidance document from the agency
You may also be interested in...
DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks
Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.
Device Firms Want Their Own Guidelines On Risk Information In Ads
FDA's draft guidance on presentation of risk information in advertisements fails to adequately distinguish between devices and drugs, according to device trade group AdvaMed
Device Firms Want Their Own Guidelines On Risk Information In Ads
FDA's draft guidance on presentation of risk information in advertisements fails to adequately distinguish between devices and drugs, according to device trade group AdvaMed